Selecting a therapeutic antibody that will become commercially successful is often a huge gamble, with candidates potentially failing at any stage of development. Those that are rushed through the ...

YUMAB uses libraries of close to germline origin ... The resulting antibodies are maximally de-risked with respect to immunogenicity, because every V region sequence has been expressed in a ...